KLIMENTOVA, E.A.,
GILYAZOVA, I.R.,
BERMISHEVA, M.A.,
BLINNIKOVA, A. M.,
SAFIULLIN, R.I.,
IZMAILOV, A.A.,
YANG, B.,
PAVLOV ., V.N,
KHUSNUTDINOVA, E.K. (2020) are accompanied by inactivation of the von Hippel–Lindau gene (VHL). It is known that VHL is a
target for several
Asadullina, D.D.,
Gilyazova, I.R.,
Ivanova, E.A.,
Izmailova, S.M.,
Gilyazova, G.R.,
Pavlov, V.N.,
Khusnutdinova, E.K. (2024) inhibitors (ICI) still have limited
therapeutic efficacy. A growing number of investigations has demonstrated
and for
targeted therapy of age-associated pathologies, including malignant neoplasms. In this regard, the study
Fedorova, Yu. Yu.,
Aminova, E.T.,
Faishanova, R.R.,
Zagitov, I.R.,
Romanova, A.R.,
Nurgalieva, A.Kh.,
Andreeva, E.A.,
Darvish, M.,
Khusnutdinova, E.K.,
Prokofyeva, D.S. (2025) as
therapeutic pathomorphosis, not identify statistically significant differences in the methylation levels
ЭПИГЕНЕТИКА АГРЕССИВНОГО ПОВЕДЕНИЯMUSTAFIN, R.N.,
KHUSNUTDINOVA, E.K.,
KAZANTSEVA, A.V.,
ENIKEEVA, R.F.,
DAVYDOVA, Y.D.,
KARUNAS, A.S.,
MALYKH, S.B.,
МУСТАФИН Р. Н.,
КАЗАНЦЕВА А.В.,
ЕНИКЕЕВА Р.Ф.,
ДАВЫДОВА Ю.Д.,
КАРУНАС А.С.,
МАЛЫХ С.Б.,
ХУСНУТДИНОВА Э.К. (2019) of the individual nature of epigenetic modifications for the further
targeted action and their correction.